29 results on '"Rueda JD"'
Search Results
2. Evaluacion Economica Del Manejo Farmacologico Del Paciente Con Hiperplasia Prostatica Benigna En Colombia
- Author
-
Cortés, V, primary, Rueda, JD, additional, Lopez, H, additional, Villegas, J, additional, and Rosselli, D, additional
- Published
- 2015
- Full Text
- View/download PDF
3. Budget impact of thrombolysis for myocardial infarction with Supra ST in Colombia
- Author
-
Rosselli, D, primary, Moreno, A, additional, Rueda, JD, additional, and Herran, S, additional
- Published
- 2013
- Full Text
- View/download PDF
4. PUK5 - Evaluacion Economica Del Manejo Farmacologico Del Paciente Con Hiperplasia Prostatica Benigna En Colombia
- Author
-
Cortés, V, Rueda, JD, Lopez, H, Villegas, J, and Rosselli, D
- Published
- 2015
- Full Text
- View/download PDF
5. PMS7 - Costo-Utilidad de Un Esquema Inicial de Tratamiento Con Tofacitinib Comparado Con Terapia Biologica Anti-Tnf en Pacientes Adultos Con Artritis Reumatoide Que Han Presentado Respuesta Inadecuada a Metotrexato en Venezuela
- Author
-
Rosselli, D, Rueda, JD, Andrade, AJ, and Prieto, VA
- Published
- 2015
- Full Text
- View/download PDF
6. PCV43 - Budget impact of thrombolysis for myocardial infarction with Supra ST in Colombia
- Author
-
Rosselli, D, Moreno, A, Rueda, JD, and Herran, S
- Published
- 2013
- Full Text
- View/download PDF
7. PUK5 Evaluacion Economica Del Manejo Farmacologico Del Paciente Con Hiperplasia Prostatica Benigna En Colombia
- Author
-
Cortés, V, Rueda, JD, Lopez, H, Villegas, J, and Rosselli, D
- Full Text
- View/download PDF
8. PCV43 Budget impact of thrombolysis for myocardial infarction with Supra ST in Colombia
- Author
-
Rosselli, D, Moreno, A, Rueda, JD, and Herran, S
- Full Text
- View/download PDF
9. PMS7 Costo-Utilidad de Un Esquema Inicial de Tratamiento Con Tofacitinib Comparado Con Terapia Biologica Anti-Tnf en Pacientes Adultos Con Artritis Reumatoide Que Han Presentado Respuesta Inadecuada a Metotrexato en Venezuela
- Author
-
Rosselli, D, Rueda, JD, Andrade, AJ, and Prieto, VA
- Subjects
health care economics and organizations - Full Text
- View/download PDF
10. Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia.
- Author
-
Rosselli D, Rueda JD, Solano M, Rosselli, Diego, Rueda, Juan-David, and Solano, Martha
- Abstract
Mucopolysaccharidosis VI is an autosomal recessive lysosomal storage disorder associated with severe disability and premature death. The presence of a mucopolysaccharidosis-like disease in indigenous ethnic groups in Colombia can be inferred from archaeological findings. There are several indigenous patients with mucopolysaccharidosis VI currently receiving enzyme replacement therapy. We discuss the ethical and economic considerations, regarding both direct and indirect costs, of a high-cost orphan disease in a marginalised minority population in a developing country. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer.
- Author
-
Fang C, Markuzon N, Patel N, and Rueda JD
- Subjects
- Humans, Natural Language Processing, Quality of Life, Carcinoma, Hepatocellular, Stomach Neoplasms, Liver Neoplasms
- Abstract
Objectives: This study sought to explore the use of novel natural language processing (NLP) methods for classifying unstructured, qualitative textual data from interviews of patients with cancer to identify patient-reported symptoms and impacts on quality of life., Methods: We tested the ability of 4 NLP models to accurately classify text from interview transcripts as "symptom," "quality of life impact," and "other." Interview data sets from patients with hepatocellular carcinoma (HCC) (n = 25), biliary tract cancer (BTC) (n = 23), and gastric cancer (n = 24) were used. Models were cross-validated with transcript subsets designated for training, validation, and testing. Multiclass classification performance of the 4 models was evaluated at paragraph and sentence level using the HCC testing data set and analyzed by the one-versus-rest technique quantified by the receiver operating characteristic area under the curve (ROC AUC) score., Results: NLP models accurately classified multiclass text from patient interviews. The Bidirectional Encoder Representations from Transformers model generally outperformed all other models at paragraph and sentence level. The highest predictive performance of the Bidirectional Encoder Representations from Transformers model was observed using the HCC data set to train and BTC data set to test (mean ROC AUC, 0.940 [SD 0.028]), with similarly high predictive performance using balanced and imbalanced training data sets from BTC and gastric cancer populations., Conclusions: NLP models were accurate in predicting multiclass classification of text from interviews of patients with cancer, with most surpassing 0.9 ROC AUC at paragraph level. NLP may be a useful tool for scaling up processing of patient interviews in clinical studies and, thus, could serve to facilitate patient input into drug development and improving patient care., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
12. Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force.
- Author
-
Padula WV, Kreif N, Vanness DJ, Adamson B, Rueda JD, Felizzi F, Jonsson P, IJzerman MJ, Butte A, and Crown W
- Subjects
- Economics, Medical, Humans, Machine Learning, Outcome Assessment, Health Care methods, Artificial Intelligence, Checklist
- Abstract
Advances in machine learning (ML) and artificial intelligence offer tremendous potential benefits to patients. Predictive analytics using ML are already widely used in healthcare operations and care delivery, but how can ML be used for health economics and outcomes research (HEOR)? To answer this question, ISPOR established an emerging good practices task force for the application of ML in HEOR. The task force identified 5 methodological areas where ML could enhance HEOR: (1) cohort selection, identifying samples with greater specificity with respect to inclusion criteria; (2) identification of independent predictors and covariates of health outcomes; (3) predictive analytics of health outcomes, including those that are high cost or life threatening; (4) causal inference through methods, such as targeted maximum likelihood estimation or double-debiased estimation-helping to produce reliable evidence more quickly; and (5) application of ML to the development of economic models to reduce structural, parameter, and sampling uncertainty in cost-effectiveness analysis. Overall, ML facilitates HEOR through the meaningful and efficient analysis of big data. Nevertheless, a lack of transparency on how ML methods deliver solutions to feature selection and predictive analytics, especially in unsupervised circumstances, increases risk to providers and other decision makers in using ML results. To examine whether ML offers a useful and transparent solution to healthcare analytics, the task force developed the PALISADE Checklist. It is a guide for balancing the many potential applications of ML with the need for transparency in methods development and findings., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
13. Effect of biomolecules derived from human platelet-rich plasma on the ex vivo expansion of human adipose-derived mesenchymal stem cells for clinical applications.
- Author
-
Becerra-Bayona SM, Solarte VA, Alviar Rueda JD, Sossa CL, and Arango-Rodríguez ML
- Subjects
- Cell Differentiation, Cell Proliferation, Cells, Cultured, Humans, Osteogenesis, Mesenchymal Stem Cells metabolism, Platelet-Rich Plasma metabolism
- Abstract
Mesenchymal stem cells are a tool in cell therapies but demand a large cell number per treatment, for that, suitable culture media is required which contains fetal bovine serum (FBS). However, for cell-based therapy applications, the use of FBS is problematic. Several alternatives to FBS have been explored, including human derivatives from platelet-rich plasma (hD-PRP). Although various studies have evaluated the impact of hD-PRP on MSC proliferation and differentiation, few of them have assessed their influence on processes, such as metabolism and gene expression. Here, we cultured human adipose-derived MSCs (hAD-MSCs) in media supplemented with either 10% hD-PRP (hD-PRP-SM) or 10% FBS (FBS-SM) in order to characterize them and evaluate the effect of hD-PRP on cell metabolism, gene expression of associated regenerative factors, as well as chromosome stability during cell expansion. We found that hAD-MSCs cultured in hD-PRP-SM have a greater cell elongation but express similar surface markers; in addition, hD-PRP-SM promoted a significant osteogenic differentiation in the absence of differentiation medium and increased the growth rate, maintaining chromosomal stability. In terms of cell metabolic profile, hAD-MSC behavior did not reveal any differences between both culture conditions. Conversely, significant differences in collagen I and angiopoietin 2 expression were observed between both conditions. The present results suggest that hD-PRP may influence hAD-MSC behavior., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
14. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.
- Author
-
Ronnebaum S, Aly A, Patel D, Benavente F, and Rueda JD
- Abstract
Aim: To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma., Materials & Methods: Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched., Results: From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms., Conclusions: Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes., Competing Interests: Financial & competing interests disclosure Funding for this study was provided by AstraZeneca. A Aly and F Benavente are former employees of AstraZeneca. J-D Rueda is an employee and stockholder of AstraZeneca. S Ronnebaum and D Patel are employees of OPEN Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript., (© 2021 Sarah Ronnebaum.)
- Published
- 2021
- Full Text
- View/download PDF
15. Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency.
- Author
-
Rueda JD, Sieluk J, Sandhaus RA, and Mullins CD
- Subjects
- Budgets standards, Budgets statistics & numerical data, Cost-Benefit Analysis statistics & numerical data, Humans, Models, Economic, Rare Diseases economics, Budgets methods, Cost-Benefit Analysis methods, Rare Diseases therapy
- Abstract
Objectives: There are challenges in conducting a budget impact analysis (BIA) for rare disorders. Through this case study, we present some challenges and limitations of a BIA of managing patients affected with alpha-1 antitrypsin deficiency (AATD). We explored a conceptual basis and barriers for health services researchers interested in quantifying budget impacts of rare disease management program (DMP)., Methods: We developed a static budget impact cost calculator model in Microsoft Excel, obtaining the clinical impact of a DMP from the literature and translating it into costs using OLDW. Cost inputs and resource use was obtained from 2010 to 2015 claims data using the OLDW. Insurers' payments were calculated and categorized into the following cost buckets: physician visits, emergency room visits, inpatients stays, augmentation therapy, other prescription drugs costs, and other costs., Results: Data were based on 6832 patients with alpha-1 antitrypsin deficiency identified among over 21 million OLDW enrollees observed between January 1, 2010, and December 31, 2015. The introduction of a DMP was estimated to decrease costs of the management of patients with alpha-1 antitrypsin deficiency by $13.5 million over 5 years. The savings attributed to the program over the 5-year time horizon are due to 2555 exacerbations, 5180 emergency room visits, 9342 specialist visits, and 105 358 general practitioner visits avoided., Conclusions: A comprehensive DMP for a rare condition might provide cost savings to a health plan. BIAs for rare disease may be more informative if they focus on DMPs rather than on individual drugs., (Copyright © 2020 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
16. A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data.
- Author
-
Slejko JF, Rueda JD, Trovato JA, Gorman EF, Betz G, Arcona S, Zacker C, and Stuart B
- Subjects
- Administration, Oral, Comparative Effectiveness Research statistics & numerical data, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Medication Adherence statistics & numerical data, Treatment Outcome, Antineoplastic Agents, Immunological administration & dosage, Comparative Effectiveness Research methods, Neoplasms drug therapy
- Abstract
Background: Understanding the real-world use of oral oncolytics is essential to assess drug effectiveness. Retrospective analyses using medical and pharmacy claims data allow observation of drug use patterns and health outcomes. However, studies of medication adherence to oral oncolytics may not be sufficient in characterizing exposure because they typically measure refill frequency, not the administered dose or dose changes. Patients who appear fully adherent by traditional measures may be receiving different doses and experiencing differing effectiveness. Relative dose intensity (RDI) is a measure that has been used for intravenous drugs to capture the amount of a particular chemotherapeutic agent administered per unit of time (dose intensity), expressed as the fraction of the amount recommended in evidence-based guidelines. Such a measure would be useful for real-world studies of comparative effectiveness to characterize patient exposure to oral oncolytics., Objective: To identify studies that used administrative claims data to measure real-world oral oncolytic dose intensity, RDI, or similar constructs., Methods: Two health sciences librarians conducted a literature search (PubMed, January 1, 1809-February 6, 2018) including terms in each of the following concept areas: oncology drugs, dosage, and retrospective data sources. At least 2 reviewers scanned each title and abstract of publications retrieved from PubMed. Abstracts that indicated the study reported dose or related concepts and oral oncolytics using retrospective data sources were marked for full-text review. During full-text review, papers were excluded if they did not study oral oncolytics (i.e., only described intravenous chemotherapy); if they did not report drug dosage; or if the study was not retrospective. Resulting studies were included for full-text data extraction., Results: Of the 1,640 publications returned from the search, 41 were marked for full-text review. Full-text review established that 17 studies addressed a concept related to dose of oral oncolytics using retrospective data. Twenty-four studies were excluded: 11 did not measure dose; 9 did not study oral oncolytics; and 4 were not retrospective studies. Among the 17 articles marked for extraction, 5 articles reported dose intensity or RDI using medical records or electronic health record (EHR) data., Conclusions: This study reveals not only the need for a claims-based measure of dose intensity for oral oncolytics, but also provides a basis for the development of such a measure based on previous EHR-based studies. While several claims data studies have characterized oral oncolytic dosing and duration, we found that no studies combined these dimensions into a single measure such as dose intensity. Methods using EHR data may be translatable to a claims data study. Future research is needed to develop and validate such measures., Disclosures: Novartis Pharmaceuticals provided funding for this study and is a manufacturer of oral onalytics, which is under study in this article. Arcona and Zacker are employees of Novartis. Slejko reports grants from PhRMA, PhRMA Foundation, and Takeda Pharmaceuticals and consulting fees from Pfizer, outside the submitted work. Stuart reports consulting fees from the University of Maryland during the study. The other authors have nothing to disclose. The preliminary findings of this study were presented in a poster at AMCP Nexus 2018, October 22-25, 2018, in Orlando, FL.
- Published
- 2019
- Full Text
- View/download PDF
17. Impact of formulary restrictions on medication intensification in diabetes treatment.
- Author
-
Stuart BC, Slejko JF, Rueda JD, Cooke CE, Shen X, Roberto P, Ciarametaro M, and Dubois R
- Subjects
- Aged, Female, Humans, Male, Retrospective Studies, United States, Diabetes Mellitus, Type 2 drug therapy, Formularies as Topic, Hypoglycemic Agents economics, Hypoglycemic Agents therapeutic use, Medicare Part D economics
- Abstract
Objectives: To explore formulary restrictions on noninsulin antihyperglycemic drugs (NIADs) in Medicare Part D plans and to estimate the impact of formulary restrictions on use of NIADs among low-income subsidy (LIS) recipient enrollees with type 2 diabetes (T2D) undergoing treatment intensification., Study Design: Retrospective cohort study., Methods: A cohort of 2919 LIS enrollees with T2D receiving metformin monotherapy during the first quarter of 2012 who intensified treatment later in the year was tracked to assess selection of and days' supply with sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and other NIADs. We tested whether being enrolled in a Part D plan with significant formulary restrictions on sole-source brand name NIADs reduced the likelihood of receiving such agents and, if so, what the impact was on days of therapy with the second agent. A 2-part regression model was estimated with explanatory variables for plan-level restrictions and individual covariates., Results: We found that 63% of study subjects initiated a sulfonylurea, 25% a DPP-4 inhibitor, and 12% another NIAD. Greater restrictions on DPP-4 inhibitors as a class were associated with small reductions in initiation of DPP-4 inhibitors and a concomitant increase in use of sulfonylureas, but neither effect was statistically significant. For individual DPP-4 inhibitors, step therapy requirements on sitagliptin and formulary exclusion of saxagliptin resulted in significant reductions in uptake of the specific drugs but had no significant impact on total days' supply of antihyperglycemic therapy., Conclusions: Part D formulary restrictions on sole-source brand name NIADs had little impact on patterns of treatment intensification for T2D among LIS recipients enrolled in Medicare Part D plans in 2012.
- Published
- 2018
18. Solving the negative impact of congestion in the postanesthesia care unit: a cost of opportunity analysis.
- Author
-
Ruiz-Patiño A, Acosta-Ospina LE, and Rueda JD
- Subjects
- Anesthesia Department, Hospital economics, Anesthesia Department, Hospital organization & administration, Anesthesia Department, Hospital statistics & numerical data, Colombia, Hospital Units statistics & numerical data, Humans, Length of Stay economics, Operating Rooms organization & administration, Operating Rooms statistics & numerical data, Patient Transfer statistics & numerical data, Prospective Studies, Time Factors, Anesthesia Recovery Period, Crowding, Hospital Costs statistics & numerical data, Hospital Units organization & administration, Length of Stay statistics & numerical data, Patient Transfer organization & administration, Postoperative Care economics
- Abstract
Background: Congestion in the postanesthesia care unit (PACU) leads to the formation of waiting queues for patients being transferred after surgery, negatively affecting hospital resources. As patients recover in the operating room, incoming surgeries are delayed. The purpose of this study was to establish the impact of this phenomenon in multiple settings., Methods: An operational mathematical study based on the queuing theory was performed. Average queue length, average queue waiting time, and daily queue waiting time were evaluated. Calculations were based on the mean patient daily flow, PACU length of stay, occupation, and current number of beds. Data was prospectively collected during a period of 2 months, and the entry and exit time was recorded for each patient taken to the PACU. Data was imputed in a computational model made with MS Excel. To account for data uncertainty, deterministic and probabilistic sensitivity analyses for all dependent variables were performed., Results: With a mean patient daily flow of 40.3 and an average PACU length of stay of 4 hours, average total lost surgical opportunity time was estimated at 2.36 hours (95% CI: 0.36-4.74 hours). Cost of opportunity was calculated at $1592 per lost hour. Sensitivity analysis showed that an increase of two beds is required to solve the queue formation., Conclusions: When congestion has a negative impact on cost of opportunity in the surgical setting, queuing analysis grants definitive actions to solve the problem, improving quality of service and resource utilization., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
19. Examining psychotropic medication use among youth in the U.S. by race/ethnicity and psychological impairment.
- Author
-
Cook BL, Carson NJ, Kafali EN, Valentine A, Rueda JD, Coe-Odess S, and Busch S
- Subjects
- Adolescent, Black or African American ethnology, Child, Child, Preschool, Female, Humans, Male, United States ethnology, White People ethnology, Black or African American statistics & numerical data, Drug Prescriptions statistics & numerical data, Hispanic or Latino statistics & numerical data, Mental Disorders drug therapy, Mental Disorders ethnology, Psychotropic Drugs therapeutic use, White People statistics & numerical data
- Abstract
Objective: Clinical practice guidelines underscore the need for careful evaluation of the risk-benefit ratio of psychotropic medications treating mental health disorders among youth. While it is well known that racial/ethnic disparities exist in psychotropic medication use, little is known about whether these differences are driven by over-prescribing among white youth, under-prescribing among minority youth, or both. To build evidence in this area, this study examined racial/ethnic differences in the prescription of psychotropic medications among youth with and without psychological impairment., Methods: Secondary data on two-year medication use from the 2004-2011 Medical Expenditure Panel Surveys were analyzed. We capitalized on two-year panel data, creating variables that allow for differential sequencing of psychological impairment and medication prescription (e.g., impairment in year 1 or year 2, and a psychotropic medication fill in year 2). Statistical differences were determined using unadjusted rate comparisons and logistic regression models, after adjustment for socio-contextual and health status characteristics., Results: Compared to Black and Latino youth with psychological impairment, White youth were more likely to be prescribed psychotropic medications when impaired. Among youth never having psychological impairment, White youth were also more likely to be prescribed medications compared to their racial/ethnic minority counterparts., Conclusions: Differences in rates of medication use among youth with and without impairment suggest poor medication targeting across racial/ethnic groups. These results, combined with recent psychotropic medication risk warnings and concerns over increases in psychotropic medication use among youth, suggest that a continued emphasis on accurate targeting of prescribing patterns is needed across racial/ethnic groups., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
20. Framework for enhancing clinical practice guidelines through continuous patient engagement.
- Author
-
Armstrong MJ, Rueda JD, Gronseth GS, and Mullins CD
- Subjects
- Clinical Protocols standards, Patient Participation, Practice Guidelines as Topic, Quality Improvement organization & administration
- Abstract
Background: Patient engagement in clinical practice guideline (CPG) development is recommended by multiple institutions and instruments measuring guideline quality. Approaches to engaging patients, however, vary between oversight organizations, quality tools and guideline developers., Objective: We propose a ten-step framework outlining steps and options for patient engagement in guideline development with the goal of highlighting steps for patient engagement and methods by which this can be achieved., Discussion: This framework provides a model for continuous patient engagement in CPGs by outlining ten steps of guideline development occurring at the levels of the developer/committee and the individual guideline project. At the developer level, patients can assist in topic nomination (step 1), topic prioritization (step 2) and guideline development group selection (step 3). Within specific guideline projects, patients' opinions may be incorporated when framing the question (step 4), creating an analytic framework and research plan (step 5), conducting the systematic review and conclusion formation (step 6), development of recommendations (step 7) and dissemination and implementation (step 8). At the end of process, patients can again be engaged at the developer level by helping determine when guidelines need updating (step 9) and evaluating the developer's approach to patient engagement (step 10)., Conclusions: Patient engagement at each CPG development step has different purposes, mechanisms, advantages and disadvantages, and implications for resource utilization. This framework can serve as a resource for guideline developers desiring to increase patient engagement and reference for researchers investigating engagement methodology at different steps of the CPG lifecycle., (© 2016 The Authors. Health Expectations Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
21. Cost-effectiveness of kidney transplantation compared with chronic dialysis in end-stage renal disease.
- Author
-
Rosselli D, Rueda JD, and Diaz CE
- Abstract
To estimate the costs and effectiveness measured in quality-adjusted life years (QALY) of kidney transplantation compared with dialysis in adults suffering from end-stage renal disease from the perspective of the Colombian healthcare system, we designed a Markov model with monthly cycles over a five-year time horizon and eight transitional states, including death as an absorbing state. Transition probabilities were obtained from international registries, costs from different local sources [case studies, official tariffs (ISS 2001 + 35%) for procedures and SISMED for medications]. Data were validated by an expert panel and we performed univariate, multivariate and probabilistic sensitivity analyses. Effectiveness indicators were months of life gained, months of dialysis averted and deaths prevented. The annual discount rate was 3% and the cost-utility threshold (willingness to pay) was three times gross domestic product (GDP) = USD 20,000 per QALY. The costs were adopted in US dollars (USD) using the 2012 average exchange rate (1 USD = COP$ 1798). The discounted average total cost for five years was USD 76,718 for transplantation and USD 76,891 for dialysis, with utilities 2.98 and 2.10 QALY, respectively. Additionally, renal transplantation represented 6.9 months gained, 35 months in dialysis averted per patient and one death averted for each of the five patients transplanted in five years. We conclude that renal transplantation improves the overall survival rates and quality of life and is a cost-saving alternative compared with dialysis.
- Published
- 2015
- Full Text
- View/download PDF
22. Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia.
- Author
-
Rosselli D, Rueda JD, Silva MD, and Salcedo J
- Abstract
Introduction: Intensive care units (ICUs) are the most frequent setting for serious medical errors, which not only have serious health consequences but also an economic impact. In this article, using a theoretical model, we evaluate four medication administration systems: conventional preparation by nursing staff, MINIBAG Plus delivery system, compounding center preparation, and premix drugs., Methods: We designed a decision tree model from a third-party payer perspective, and the time horizon of the acute event. Local costs, in Colombian pesos (US $1 = 1784 COP$), were obtained from tariff manuals, medication costs from Sismed information system, and clinical variables from the published literature, and uncertainty was dealt with by an expert panel. The drug used for the model was dopamine., Results: Average costs for each dopamine dose delivered were $46,995 for premix, $47,625 for compounding center, $101,934 for MINIBAG Plus, and $108,870 for drug prepared in the ICU. The variability of these results is higher for compounding center than for premix, and even higher for MINIBAG Plus and nurse delivery., Conclusions: The use of premix drugs can be a cost-saving strategy, which decreases medical errors in drug administration in the ICU, particularly if it is part of an integral error reduction program., (Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
23. [Methods for evaluating large-scale nutrition programs in latin america: an integrative review].
- Author
-
Álvarez Castaño LS, Pérez Isaza EJ, Góez Rueda JD, Rivera Jaramillo A, and Peña Ochoa C
- Subjects
- Adult, Child, Health Education, Humans, Latin America, Nutritional Status, Program Evaluation statistics & numerical data, Public Policy, Health Promotion organization & administration, Program Evaluation methods
- Abstract
Introduction: The evaluation of social programs is a field of knowledge in consolidation, involving different disciplines. It uses the social research tools but have particular goals that distinguish from it., Objective: This study aimed to identify methodological designs currently used to evaluate the nutritional programs in Latin America, including the types of studies conducted on the assessments, the dimensions assessed and indicators used., Methods: An integrative revision was carried out. Several electronic databases were consulted; likewise web pages of international agencies and institutions were searched by using a manual process., Results: 92 evaluations of 40 programs were analyzed, we found that in most cases no explicit methodological design was used in the evaluation. In those cases where if do, mostly showed three designs: consistency and results, multidimensional model and triangulation of methods. The dimensions mostly assessed are the program's impact and outcomes and to a lesser extent its structure and process. The types of study used to measure the impact of nutritional programs remain quantitative in nature especially quasi-experimental, however there is an effort made by some scholars by using qualitative tools that account for the perceptions of the actors involved., Conclusions: We found an interest in some institutions for carrying out assessments based on new paradigms and exploring combination of methods, objectives and indicators., (Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
24. Cost-Effectiveness Of Dabigatran Compared With Warfarin, Apixaban, Rivaroxaban And Low Molecular Weight Heparins For The Treatment And Secondary Prevention Of Venous Thromboembolism In Colombia.
- Author
-
Rosselli D, Rueda JD, Wolowacz S, Brockbank J, and Abeysinghe S
- Published
- 2014
- Full Text
- View/download PDF
25. The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.
- Author
-
Castro HE, Briceño MF, Casas CP, and Rueda JD
- Abstract
First evidence of cases of haemophilia dates from ancient Egypt, but it was when Queen Victoria from England in the 19th century transmitted this illness to her descendants, when it became known as the "royal disease". Last decades of the 20th century account for major discoveries that improved the life expectancy and quality of life of these patients. The history and evolution of haemophilia healthcare counts ups and downs. The introduction of prophylactic schemes during the 1970s have proved to be more effective that the classic on-demand replacement of clotting factors, nevertheless many patients managed with frequent plasma transfusions or derived products became infected with the Human Immunodeficiency Virus (HIV) and Hepatitis C virus during the 1980s and 1990s. Recombinant factor VIII inception has decreased the risk of blood borne infections and restored back longer life expectancies. Main concerns for haemophilia healthcare are shifting from the pure clinical aspects to the economic considerations of long-term replacement therapy. Nowadays researchers' attention has been placed on the future costs and cost-effectiveness of costly long-term treatment. Equity considerations are relevant as well, and alternative options for less affluent countries are under the scope of further research. The aim of this review was to assess the evidence of different treatment options for haemophilia type A over the past four decades, focusing on the most important technological advances that have influenced the natural course of this "royal disease".
- Published
- 2014
- Full Text
- View/download PDF
26. Hyperproteic hypocaloric enteral nutrition in the critically ill patient: A randomized controlled clinical trial.
- Author
-
Rugeles SJ, Rueda JD, Díaz CE, and Rosselli D
- Abstract
Introduction: Our aim was to evaluate the impact of hyperproteic hypocaloric enteral feeding on clinical outcomes in critically ill patients, particularly on severity of organic failure measured with the Sequential Organ Failure Assessment (SOFA)., Materials and Methods: In a double blind clinical trial, 80 critically ill adult patients were randomized to hyperproteic hypocaloric or to isocaloric enteral nutrition; all patients completed follow-up of at least 4 days. Prescribed caloric intake was: Hyperproteic hypocaloric enteral nutrition (15 kcal/kg with 1.7 g/kg of protein) or isocaloric enteral nutrition (25 kcal/kg with 20% of the calories as protein). The main outcome was the differences in delta SOFA at 48 h. Secondary outcomes were intensive care unit (ICU) length of stay, days on ventilator, hyperglycemic events, and insulin requirements., Results: There were no differences in SOFA score at baseline (7.5 (standard deviation (SD) 2.9) vs 6.7 (SD 2.5) P = 0.17). The total amount of calories delivered was similarly low in both groups (12 kcal/kg in intervention group vs 14 kcal/kg in controls), but proteic delivery was significantly different (1.4 vs 0.76 g/kg, respectively P ≤ 0.0001). The intervention group showed an improvement in SOFA score at 48 h (delta SOFA 1.7 (SD 1.9) vs 0.7 (SD 2.8) P = 0.04) and less hyperglycemic episodes per day (1.0 (SD 1.3) vs 1.7 (SD 2.5) P = 0.017)., Discussion: Enteral hyperproteic hypocaloric nutrition therapy could be associated with a decrease in multiple organ failure measured with SOFA score. We also found decreased hyperglycemia and a trend towards less mechanical ventilation days and ICU length of stay.
- Published
- 2013
- Full Text
- View/download PDF
27. The effects of socioeconomic status and short stature on overweight, obesity and the risk of metabolic complications in adults.
- Author
-
Castaño LS, Restrepo AE, Rueda JD, Aguirre CC, and López LP
- Abstract
Objective: to observe the relationship between socioeconomic status, height and nutritional problems related to obesity, overweight and risk of metabolic complications in men and women of Medellin (Colombia)., Methods: cross-sectional study with a sample of 5556 adults between 18 and 69 years of age. We assessed weight, height and waist circumference. Socioeconomic variables were evaluated by family income, socioeconomic stratum and academic level achieved., Results: we found that in men and women the height reached in adulthood is associated with socioeconomic conditions as measured by the socioeconomic strata and family income. In women, height, age, and socioeconomic strata are associated with obesity, overweight and risk of obesity, and risk of metabolic complications., Conclusion: These results are not only from individual unhealthy habits, such as eating patterns based on high density foods combined with low energy expenditure, but also from the cumulative effect of food deprivation throughout life. Therefore, policies intended to prevent them should take a preventive approach that begins before birth and continues during childhood and adulthood.
- Published
- 2013
28. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
- Author
-
Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, and Barsic B
- Subjects
- Child, Preschool, Hospitalization statistics & numerical data, Humans, Infant, Infant, Newborn, Palivizumab, Randomized Controlled Trials as Topic, Antibodies, Monoclonal, Humanized therapeutic use, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Background: Respiratory syncytial virus (RSV) is one of the most important viral pathogens causing acute respiratory infections in children. It results in about 3.4 million hospitalisations annually in children under five. Palivizumab is an anti-RSV monoclonal antibody, administered intramuscularly at a dose of 15 mg/kg once every 30 days. The efficacy and safety of palivizumab has been evaluated in multicentre, randomised controlled trials (RCTs) and a large number of economic evaluations (EEs) have tested its cost-effectiveness., Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups., Search Methods: We searched CENTRAL 2012, Issue 7, MEDLINE (1996 to July week 4, 2012), EMBASE (1996 to August 2012), CINAHL (1996 to August 2012) and LILACS (1996 to August 2012) for studies of effectiveness and safety. We searched the NHS Economic Evaluations Database (NHS EED 2012, Issue 4), Health Economics Evaluations Database (HEED, 9 August 2012) and Paediatric Economic Database Evaluations (PEDE, 1980 to 2009), MEDLINE (1996 to July week 4, 2012) and EMBASE (1996 to August 2012) for economic evaluations., Selection Criteria: We included RCTs comparing palivizumab prophylaxis with a placebo, no prophylaxis or another type of prophylaxis in preventing serious lower respiratory tract disease caused by RSV in paediatric patients at high risk. We included cost-effectiveness analyses and cost-utility analyses comparing palivizumab prophylaxis with no prophylaxis., Data Collection and Analysis: Two review authors independently assessed risk of bias for the included studies and extracted data for both the RCTs and EEs. We calculated risk ratios (RRs) and their associated 95% confidence intervals (CIs) for dichotomous outcomes and for adverse events (AEs). We provided a narrative summary of results for continuous outcomes, due to missing data on standard deviations. We performed fixed-effect meta-analyses for the estimation of pooled effects whenever there was no indication of heterogeneity between included RCTs. We summarised the results reported in included EEs, such as incremental costs, incremental effectiveness, and incremental cost-effectiveness and/or cost-utility ratios (ICERs), and we calculated ICER present values in 2011 Euros for all studies., Main Results: Of the seven available RCTs, three compared palivizumab with a placebo in a total of 2831 patients, and four compared palivizumab with motavizumab in a total of 8265 patients. All RCTs were sponsored by the drug manufacturing company. The overall quality of RCTs was good, but for most of the outcomes assessed only data from two studies contributed to the analysis. Palivizumab prophylaxis was associated with a statistically significant reduction in RSV hospitalisations (RR 0.49, 95% CI 0.37 to 0.64) when compared to placebo. When compared to motavizumab, palivizumab recipients showed a non-significant increase in the risk of RSV hospitalisations (RR 1.36, 95% CI 0.97 to 1.90). In both cases, the proportion of children with any AE or any AE related to the study drug was similar between the two groups.In terms of economic evidence, we included 34 studies that reported cost-effectiveness and/or cost-utility data for palivizumab prophylaxis compared with no prophylaxis, in high-risk children with different underlying medical conditions. The overall quality of EEs was good, but the variations in modelling approaches were considerable across the studies, leading to big differences in cost-effectiveness results. The cost-effectiveness of palivizumab prophylaxis depends on the consumption of resources taken into account by the study authors; and on the cost-effectiveness threshold set by the healthcare sector in each country., Authors' Conclusions: There is evidence that palivizumab prophylaxis is effective in reducing the frequency of hospitalisations due to RSV infection, i.e. in reducing the incidence of serious lower respiratory tract RSV disease in children with chronic lung disease, congenital heart disease or those born preterm.Results from economic evaluations of palivizumab prophylaxis are inconsistent, implying that economic findings must be interpreted with caution. ICER values varied considerably across studies, from highly cost-effective to not cost-effective. The availability of low-cost palivizumab would reduce its inequitable distribution, so that RSV prophylaxis would be available to the poorest countries where children are at greatest risk.
- Published
- 2013
- Full Text
- View/download PDF
29. Burden of pneumococcal infection in adults in Colombia.
- Author
-
Rosselli D and Rueda JD
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Bacteremia microbiology, Bacteremia mortality, Colombia epidemiology, Female, Humans, Incidence, Male, Meningitis microbiology, Meningitis mortality, Middle Aged, Pneumococcal Infections mortality, Pneumonia, Bacterial microbiology, Pneumonia, Bacterial mortality, Prevalence, Survival Analysis, Young Adult, Bacteremia epidemiology, Meningitis epidemiology, Pneumococcal Infections epidemiology, Pneumonia, Bacterial epidemiology, Streptococcus pneumoniae isolation & purification
- Abstract
Introduction: The burden of Streptococcus pneumoniae infections is highest in children. Estimates in adult population are uncommon. We determined the burden of disease associated with pneumococcus in adults in Colombia in year 2008., Methodology: Using different data sources (official mortality records, medical databases, published literature and local epidemiological data) we estimated prevalence, incidence, mortality and disability due to bacterial pneumonia, bacterial meningitis and bacteremia of any cause for year 2008, and the fraction of these that can be attributed to S. pneumoniae., Results: A total of 63,463 DALYs are lost due to S. pneumoniae in Colombians age 15 or over. Most of this burden (51,848 DALYs, 81.7%) is due to pneumonia, followed by meningitis (9241 DALYs, 14.6%). The three conditions, overall, represent 2.03 DALYs per 1000 Colombians in that age range., Conclusions: Despite the lower incidence of pneumococcal disease in adults, as compared with children, its burden is still significant, comparable to that of schizophrenia or epilepsy. This study may provide a benchmark for future preventive interventions., (Copyright © 2012 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.